Brief: Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027
02/03/2026 14:15
March 2 (Reuters) - EyePoint Inc EYPT.O: EYEPOINT ANNOUNCES FIRST PATIENTS DOSED IN BOTH GLOBAL PHASE 3 CLINICAL TRIALS OF DURAVYU™ FOR THE TREATMENT OF DIABETIC MACULAR EDEMA EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027 EYEPOINT INC: TOPLINE DATA FOR DURAVYU IN DME ANTICIPATED IN 2H 2027 Source text: ID:nGNXc3YhH2 Further company coverage: EYPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on EyePoint
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
US STOCKS ON THE MOVE-CoreWeave, Moderna, Datadog
U.S. STOCKS ON THE MOVE-Amazon, CoreWeave, Moderna
U.S. STOCKS ON THE MOVE-Centrus Energy, Disc Medicine, Crypto
EyePoint to halve workforce after experimental drug fails second late-stage trial (updated)